Our product candidates provide opportunities to control and modify diseases, and strive to address the unmet medical needs of patients and their care partners.

Our mRNAi GOLD™ Pipeline Targets

Our pipeline is based on our proprietary mRNAi GOLD™ Platform designed to precisely target and silence disease-associated genes expressed in the liver, which represents a substantial opportunity. Through this approach, we are developing a pipeline of wholly-owned programs and partnership programs focused in areas of significant unmet need.

Picture1.png (3) Picture1.png (3)